Q-Line Biotech is poised for a strong stock market debut on Friday. Investor demand appears robust, with grey market trends showing a significant premium. The company's shares are expected to list at a higher price than the IPO issue price. Q-Line Biotech operates in the diagnostics and healthcare products segment. This positive sentiment highlights investor interest in the healthcare sector.

Bio Medica Laboratories' shares are set to list on the NSE SME platform amidst weak grey market sentiment, with the IPO currently trading at a discount. The Rs 52 crore IPO, which…

Q-Line Biotech is poised for a strong stock market debut on Friday. Investor demand appears robust, with grey market trends showing a significant premium. The company's shares are…